Acne Vulgaris - Pipeline Review, H1 2014 @ http://www.researchmoz.us/acne-vulgaris-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Acne Vulgaris - Pipeline Review, H1 2014
Acne Vulgaris - Pipeline Review, H1 2014
Summary
Global Markets Directs, Acne Vulgaris - Pipeline Review, H1 2014, provides an overview of the Acne Vulgariss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and
industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 8
list Of Figures 9
introduction 10
global Markets Direct Report Coverage 10
acne Vulgaris Overview 11
therapeutics Development 12
pipeline Products For Acne Vulgaris - Overview 12
pipeline Products For Acne Vulgaris - Comparative Analysis 13
acne Vulgaris - Therapeutics Under Development By Companies 14
acne Vulgaris - Therapeutics Under Investigation By Universities/institutes 18
acne Vulgaris - Pipeline Products Glance 19
late Stage Products 19
clinical Stage Products 20
Acne Vulgaris - Pipeline Review, H1 2014

2. early Stage Products 21
unknown Stage Products 22
acne Vulgaris - Products Under Development By Companies 23
acne Vulgaris - Products Under Investigation By Universities/institutes 25
acne Vulgaris - Companies Involved In Therapeutics Development 26
boehringer Ingelheim Gmbh 26
photocure Asa 27
valeant Pharmaceuticals International, Inc. 28
glaxosmithkline Plc 29
photopharmica Limited 30
galderma S.a. 31
toyama Chemical Co., Ltd. 32
anticancer, Inc. 33
xoma Corporation 34
quest Pharmatech Inc. 35
provectus Biopharmaceuticals, Inc. 36
phosphagenics Limited 37
foamix Ltd. 38
androscience Corporation 39
hygeia Therapeutics, Inc. 40
elorac, Inc. 41
cutanea Life Sciences 42
braintree Laboratories, Inc. 43
maruho Co., Ltd. 44
sol-gel Technologies Ltd. 45
ensoltek Co., Ltd. 46
ausio Pharmaceuticals, Llc 47
xbiotech Usa, Inc. 48
advancell 49
delenex Therapeutics Ag 50
dermira Inc. 51
dignity Sciences Ltd. 52
biomar Microbial Technologies 53
thesan Pharmaceuticals, Inc. 54
origimm E.u. 55
acne Vulgaris - Therapeutics Assessment 56
assessment By Monotherapy Products 56
assessment By Combination Products 57
assessment By Target 58
assessment By Mechanism Of Action 61
assessment By Route Of Administration 64
assessment By Molecule Type 66
drug Profiles 68
(adapalene + Benzoyl Peroxide) - Drug Profile 68
product Description 68
mechanism Of Action 68
r&d Progress 68
ozenoxacin - Drug Profile 69
product Description 69
mechanism Of Action 69
r&d Progress 69
benzoyl Peroxide - Drug Profile 71
product Description 71
mechanism Of Action 71
r&d Progress 71
e-10215 - Drug Profile 72
product Description 72
mechanism Of Action 72
r&d Progress 72
omiganan Pentahydrochloride - Drug Profile 73
product Description 73
mechanism Of Action 73
r&d Progress 73
tretinoin - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
ascj-9 - Drug Profile 76
Acne Vulgaris - Pipeline Review, H1 2014

3. product Description 76
mechanism Of Action 76
r&d Progress 76
aus-131 - Drug Profile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
methyl Aminolevulinate - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
gevokizumab - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
cb-0301 - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
minocycline - Drug Profile 86
product Description 86
mechanism Of Action 86
r&d Progress 86
drm-01 - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
bli-1100 - Drug Profile 89
product Description 89
mechanism Of Action 89
r&d Progress 89
cd2475/101 - Drug Profile 90
product Description 90
mechanism Of Action 90
r&d Progress 90
jnj-10229570-aaa - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
ra-18c3 - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
cd-5789 - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
nvn-1000 - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
onabotulinumtoxina - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
ark-e021 - Drug Profile 98
product Description 98
mechanism Of Action 98
r&d Progress 98
sl-017 - Drug Profile 99
product Description 99
mechanism Of Action 99
r&d Progress 99
gsk-1940029 - Drug Profile 101
product Description 101
mechanism Of Action 101
r&d Progress 101
fx-125-l - Drug Profile 102
Acne Vulgaris - Pipeline Review, H1 2014

4. product Description 102
mechanism Of Action 102
r&d Progress 102
ph-10 - Drug Profile 104
product Description 104
mechanism Of Action 104
r&d Progress 104
hyg-440 - Drug Profile 106
product Description 106
mechanism Of Action 106
r&d Progress 106
sgt-tn-65 - Drug Profile 107
product Description 107
mechanism Of Action 107
r&d Progress 107
sgt-sz-91 - Drug Profile 108
product Description 108
mechanism Of Action 108
r&d Progress 108
ans-29 - Drug Profile 109
product Description 109
mechanism Of Action 109
r&d Progress 109
ad-037 - Drug Profile 110
product Description 110
mechanism Of Action 110
r&d Progress 110
drug For Acne - Drug Profile 111
product Description 111
mechanism Of Action 111
r&d Progress 111
anti Acne Vaccine - Drug Profile 112
product Description 112
mechanism Of Action 112
r&d Progress 112
small Molecule For Acne - Drug Profile 113
product Description 113
mechanism Of Action 113
r&d Progress 113
ds-109 - Drug Profile 114
product Description 114
mechanism Of Action 114
r&d Progress 114
drugs To Inhibit Gnrh Receptor For Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology And Women Health - Drug Profile 115
product Description 115
mechanism Of Action 115
r&d Progress 115
salicylic Acid - Drug Profile 116
product Description 116
mechanism Of Action 116
r&d Progress 116
lipo-4ma - Drug Profile 117
product Description 117
mechanism Of Action 117
r&d Progress 117
dlx-2323 - Drug Profile 118
product Description 118
mechanism Of Action 118
r&d Progress 118
peptide To Disrupt Bacterial Cell Membrane And Cell Wall For Acne And Skin Cancer - Drug Profile 119
product Description 119
mechanism Of Action 119
r&d Progress 119
sharon-4000 - Drug Profile 120
product Description 120
mechanism Of Action 120
r&d Progress 120
small Molecule For Acne - Drug Profile 121
Acne Vulgaris - Pipeline Review, H1 2014

5. product Description 121
mechanism Of Action 121
r&d Progress 121
drugs For Acne - Drug Profile 122
product Description 122
mechanism Of Action 122
r&d Progress 122
acne Vaccine - Drug Profile 123
product Description 123
mechanism Of Action 123
r&d Progress 123
acne Vulgaris - Recent Pipeline Updates 124
acne Vulgaris - Dormant Projects 136
acne Vulgaris - Discontinued Products 137
acne Vulgaris - Product Development Milestones 138
featured News & Press Releases 138
mar 19, 2014: Novan Announces Positive Phase 2 Results For Novel Acne Treatment 138
jun 25, 2013: Xoma's Development Partner Servier Launches Proof-of-concept Clinical Program For Gevokizumab 138
feb 28, 2013: Meda's Acnex Receives Registration Approval In Europe 139
feb 28, 2013: Novan Therapeutics On Path To Develop First Topical Acne Treatment 140
feb 19, 2013: Galderma's Epiduo Gel Obtains Fda Approval To Treat Acne In Children As Young As Nine Years Old 140
jan 07, 2013: Xoma Announces Positive Interim Results From Gevokizumab Phase Ii Study For Moderate To Severe Acne Vulgaris 141
dec 12, 2012: Xbiotech Announces Positive Phase Ii Clinical Trial Results For Mabp1 In Acne Vulgaris 142
jul 30, 2012: Watson Confirms Epiduo Gel Patent Challenge 143
jan 13, 2012: Photocure Completes Enrollment In Visonac Phase Iib Study For Acne Treatment 143
dec 21, 2011: Xoma Initiates Gevokizumab Phase Ii Study For Moderate To Severe Acne Vulgaris 143
appendix 145
methodology 145
coverage 145
secondary Research 145
primary Research 145
expert Panel Validation 145
contact Us 146
disclaimer 146
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Acne Vulgaris - Pipeline Review, H1 2014